Qiming Venture Partners Wins Three Awards at China Securities Journal's 9th Private Equity Golden Bull Awards

Recently, the "2025 Sci-Tech Innovation Investment Conference," themed "Integration of Innovation and Entrepreneurship, Intelligence Igniting a New Journey" and hosted by China Securities Journal, was held in Hefei, Anhui. At the conference, the 9th Golden Bull Awards for Equity Investment were announced. Qiming Venture Partners won the Golden Bull Award for Venture Capital Institutions (Five-Year), the Golden Bull Award for M&A Funds, and the Golden Bull Award for Best M&A Case.

Qiming Venture Partners

Wins

Golden Bull Award for Venture Capital Institutions (Five-Year)

Golden Bull Award for M&A Funds

Golden Bull Award for Best M&A Case

Selection Criteria

The awards are based on thorough research and verification of information and data, combining quantitative and qualitative evaluation with emphasis on quantitative metrics. The selection process conducts a comprehensive assessment of the complete investment and financing cycle, evaluating multiple dimensions of fundraising, investment, management, and exit. It considers participating institutions' overall fundraising capabilities, investment competence, and performance, while fully weighing factors such as the investment experience of the management team, team stability, company influence, social responsibility, and corporate governance to determine award recipients.

China Securities Journal noted that over the past year, relevant authorities have issued multiple documents encouraging the development of equity investment and venture capital, focusing on removing bottlenecks and obstacles across the "fundraising, investment, management, and exit" cycle to further improve the policy environment and regulatory framework, and actively supporting the growth of venture capital. This year's Government Work Report proposed refining differentiated regulatory systems for venture capital funds, strengthening policy-based financial support, accelerating the development of venture capital, and growing patient capital. Amid the current international landscape and domestic modern industrial system development, private equity and venture capital — as important tools for direct financing and primary vehicles for innovative capital formation — are of increasingly strategic significance. The 9th Golden Bull Awards for Equity Investment by China Securities Journal continued to emphasize "patient capital," highlighting long-term value investment and hard-tech innovation, and exploring diversified fund exit pathways.

Past Highlights

Qiming ESG | Qiming Venture Partners Donates HK$3 Million to Tai Po Hong Fuk Yuen Relief Fund for Post-Disaster Reconstruction | Bilingual Qiming Perspectives | Qiming Venture Partners' Duane Kuang: Hong Kong Has Become an Important Financing Channel for Hard-Tech Companies Going Global Qiming Honors | Qiming Venture Partners Wins Three Awards Including China Venture Capital Research Institute's 2025 China Venture Capital Industry Annual Golden Investment Award

Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns in their respective industries.

Many of Qiming's portfolio companies have grown into the most influential players in their fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), AusperBio, Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.